SAN DIEGO, Aug. 8, 2025 /CNW/ — Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced that the common shares in the capital of the Company (the “Shares”) will be voluntarily delisted from the Toronto Stock Exchange (“TSX”) at the close of markets on August 22, 2025, pursuant to the Company’s application for voluntary delisting and the satisfaction of the conditions to delist from the TSX. The delisting from the TSX will not affect the Company’s listing on the Nasdaq.
After careful consideration, the board of Oncolytics has determined that a TSX de-listing is in the best interests of the Company and its shareholders for a number of reasons, including:
- The Shares are already listed and trading on the Nasdaq, and the Company intends on maintaining such…
